PARIS (Reuters) - Ipsen said two late-stage clinical trials for its experimental hemophilia drug have been put on hold, potentially delaying the French drugmaker's entry into the blood disorders market by up to six months.
via Reuters: Health News Read More Here..
No comments:
Post a Comment